A Novel Biomarker for the Diagnosis and Early Detection of Schizophrenia

**OCR Number:** OCR 5856

**Description:**

- Biomarkers for psychiatric illnesses do not currently exist and are a critical unmet need.
- Schizophrenia is ranked as the third largest burden among all neuropsychiatric disorders by the World Health Organization's 2002 report.
- Early schizophrenia (prodromal stage) resembles depression and is difficult to accurately diagnose and treat.
- This novel serum biomarker along with another commonly assessed physiological indicator, can differentiate with schizophrenia from healthy patients individuals and those with major depression.
- Initial human proof of concept studies underway to validate.

![Graph showing biomarker levels in healthy control, depressed, and schizophrenic individuals.](image)

**Stage of Development:** Initial human proof of concept studies complete to validate in vivo findings.

**Published/Issued Patents:** [PCT App. Pub. No. WO2014018513](http://www.world知识产权异议.org)

**Licensing Contact:** Lolahon Kadiri
lolahon.kadiri@yale.edu